Apr 27, 2023
AURORA, Colo., April 27, 2023 /PRNewswire/ — Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced today that it has closed an oversubscribed Series B financing round of $58.75 million. The financing was led by Foresite Capital, with participation by Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University…
Read the full article on PR Newswire.
